Academic background&position

data loading...

1. [SCIE] Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab?bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan [JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY] - 2025-01-28
2. [SCIE] Serum 25-Hydroxyvitamin D Levels and Survival Outcomes in Advanced Biliary Tract Cancer: Results From the NIFTY Trial [CANCER MEDICINE] - 2025-01-01
3. [SCIE] Impact of Etiology on Efficacy Outcomes with Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Retrospective Analysis in Asia-Pacific [TARGETED ONCOLOGY] - 2024-11-01
4. [SCIE] Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer [CLINICAL CANCER RESEARCH] - 2024-10-15
5. [SCIE] Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study [EUROPEAN JOURNAL OF CANCER] - 2024-09-01